Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer - Top-Institutions - MDSpire

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • By

  • Yulu Wang

  • Chengyang Luo

  • Yueze Li

  • Jiayu Pei

  • Dian Wang

  • Pei Wang

  • Jing Li

  • June 12, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    First Affiliated Hospital of Zhengzhou University
    First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan

    Key Differentiators

    • Oncology

  • #2

    The University of Sydney
    The University of Sydney

    Sydney, New South Wales

    Key Differentiators

    • Oncology

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • by Yulu Wang, Chengyang Luo, Yueze Li, Jiayu Pei, Dian Wang, Pei Wang, Jing Li

  • June 12, 2026

Related Content

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

The future of neurosurgical oncology lies in cognitive neurosciences: understanding brain processing is much more valuable than surgical technology

Editorial: Cancer Immunosurveillance